This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
SYK Trades Below 52-Week High: Should You Buy, Hold or Sell the Stock?
by Indrajit Bandyopadhyay
Stryker is gaining momentum with strong Q4 results, innovative medtech solutions and high-growth market expansion. But, is the stock still a buy? Find out the key factors at play.
Will Cheaper AI Models Like DeepSeek Become a Boon? 3 Stocks to Watch
by Indrajit Bandyopadhyay
As costs related to AI models may come down, as is evident from the cheaper DeepSeek model from China, MedTech companies developing AI-based solutions like SYK, BSX and TEM are likely to gain.
Stryker Stock Falls on Deal to Sell Its U.S. Spinal Implants Business
by Zacks Equity Research
SYK announces agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC.
SYK Stock Down Despite Q4 Earnings Beat and Spine Biz Divestment Plans
by Zacks Equity Research
SYK's fourth-quarter results reflect strong segmental performance, along with a rise in operating margin.
Stryker (SYK) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 3.62% and 1.34%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Strong Segmental Performance to Drive Stryker's Q4 Earnings?
by Zacks Equity Research
SYK's fourth-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
PAHC vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. SYK: Which Stock Is the Better Value Option?
Stryker (SYK) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Stryker (SYK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
PAHC or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PAHC vs. SYK: Which Stock Is the Better Value Option?
Abbott Stock Trades at a Discounted P/B Value: To Buy or Not to Buy?
by Urmimala Biswas
ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics.
Stryker Stock Falls Despite the Agreement to Acquire Inari Medical
by Zacks Equity Research
SYK inks an agreement to acquire Inari Medical at a valuation of approximately $4.9 billion.
5 MedTech Stocks That Are Poised to Beat the Market in 2025
by Harshit Gupta
Here, we discuss five stocks that are likely to generate better than the market, driven by strong demand for existing products and the addition of innovative new devices.
HAE or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
Top Stock Reports for Tesla, Broadcom & Bank of America
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Broadcom Inc. (AVGO) and Bank of America Corporation (BAC), as well as a micro-cap stock Flanigan's Enterprises, Inc. (BDL).
Here's Why You Should Retain Stryker Stock in Your Portfolio for Now
by Zacks Equity Research
SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
3 Stocks to Keep an Eye on After Dividend Hike Announcement
by Ritujay Ghosh
Stocks like SYK, LLY and AES recently announced dividend hikes.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Phibro (PAHC) Down 2.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stryker Gains 30.2% Year to Date: What's Driving the Stock?
by Zacks Equity Research
SYK continues to witness growth on the back of a robust product line and strategic acquisitions.
The Zacks Analyst Blog Highlights Amazon.com, Stryker, Lam Research and ImmuCell
by Zacks Equity Research
Amazon.com, Stryker, Lam Research and ImmuCell are included in this Analyst Blog.
Top Research Reports for Amazon, Stryker & Lam Research
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Stryker Corporation (SYK) and Lam Research Corporation (LRCX), as well as a micro-cap stock, ImmuCell Corporation (ICCC).
PBH or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
Do Options Traders Know Something About Stryker (SYK) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Stryker (SYK) stock based on the movements in the options market lately.
Stryker Stock May Gain From Oculan Lighting Platform's Launch
by Zacks Equity Research
SYK launches the Oculan Lighting Platform to improve lighting conditions in the operating rooms and allow surgeons to perform with more accuracy.